We observed that patients with low levels of FGD3 expression had a higher incidence of lymph node metastases than those with higher levels of FGD3 expression (45.7% versus 27.6%), and the difference was significant (p < 0.001). The gene discussed is FGD3; the disease is metastatic malignant neoplasm in the lymph nodes.